FACIT Features: Portfolio company Fusion Pharma launches Phase 1 trial for next-gen radiotherapeutic

FACIT congratulates portfolio company Fusion Pharma on significant clinical development milestone.

February 25, 2019 – FACIT, an Ontario-First investor, congratulates portfolio company Fusion Pharmaceuticals on the initiation of a Phase 1, first-in-human clinical trial of lead targeted alpha therapeutic [225Ac]-FPI-1434. Fusion is an Ontario-based next generation radiotherapeutics company that was seeded by FACIT. The clinical trial will evaluate safety and tolerability of the radiotherapeutic in up to 30 patients with advanced solid tumours. Fusion is moving breakthrough technologies from bench to bedside, and helping to further strengthen Ontario’s growing biotech industry.

FACIT has supported the growth of Fusion since our early seed investment in 2015, and participated in the company’s Series A financing with other top tier healthcare investors including Johnson & Johnson Innovation-JJDC, HealthCap, TPG Biotechnology Partners, Adam Street Partners, Seroba Life Sciences, Genesys Capital, and Varian Medical Systems. Provincial stakeholders are proud to see this portfolio company achieve new milestones and support FACIT’s mandate to competitively position Ontario cancer discoveries at the forefront of emerging biotech innovations. Through strong companies like Fusion, FACIT’s pure oncology portfolio has attracted over a half billion dollars in investment, and is helping to create new avenues for economic growth in Ontario.

Read Fusion’s news release here.

About Fusion Pharmaceuticals Inc.:

Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, [225Ac]-FPI-1434, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships. For more information, please visit www.fusionpharma.com or contact info@fusionpharma.com.


David Koehler, PhD | Director, Fund Operations, FACIT | david.koehler@facit.ca


FACIT actively manages our diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development.



With critical seed funding, FACIT makes it possible for Ontario’s best cancer research discoveries to compete globally and reach patients.